# Novartis financial performance and guidance updates

> Live situation record from CLSTR: https://clstr.news/situations/novartis-financial-performance-and-guidance-updates
> Updated: 2026-10-25T23:45:13.000Z. Sources: 11. Developments: 2.

In the second quarter of 2026, Novartis reported a 1% increase in net sales, driven by priority brands such as Kisqali and Kesimpta. Despite this growth, the company saw a 19% decline in net income and flat core operating income.

By the third quarter, Novartis raised its full-year guidance for adjusted operating profit to expect low single-digit growth, reversing a previous forecast of a decline. This shift followed strong sales in cancer and multiple sclerosis medications. However, net profit dropped 70% to $1.2 billion, largely due to a $1.9 billion write-down following the failure of a clinical trial for the experimental neuromuscular treatment del-desiran.

## Timeline

### 2026-10-25: Novartis raises profit guidance following strong Q3 sales

Novartis raised its 2026 operating profit guidance following strong Q3 sales, despite a 70% net profit drop caused by a $1.9 billion write-down on a failed clinical trial.

9 sources. https://clstr.news/cluster/droneshield-reports-a261-million-in-committed-revenue-for-2026

### 2026-10-23: Novartis reports Q2 sales growth driven by priority brands

Novartis saw Q2 2026 net sales grow by 1% (3% in USD), fueled by brands like Kisqali and Scemblix, while reaffirming its full-year guidance.

2 sources. https://clstr.news/cluster/novartis-reports-q2-sales-growth-driven-by-priority-brands

---
Cite as: Novartis financial performance and guidance updates. CLSTR, https://clstr.news/situations/novartis-financial-performance-and-guidance-updates